UHSUniversal Health Services

Health care · Hospitals · NYSE

Our principal business is owning and operating, through our subsidiaries, acute care hospitals and outpatient facilities and behavioral health care facilities. 10-K, Item 1

Employees: 101,500
Headquarters: King Of Prussia, PA
CEO: Marc D. Miller
Next results: around Feb 25, 2027

Compare with peers → Embed

The numbers UHS said it expected, in its earnings releases of the last 3 years, next to what it then reported for the same period. Each target links to the sentence in the release; each result to the 10-Q or 10-K it was first reported in.

Of 2 range targets with a reported result: 2 came in above the last range given, 0 within it, 0 below it.

Target	What the company said	Reported	Result
EBITDA (company-defined) Fiscal 2026	Given $2.59B release 2026-02-26	–	No standard number
The company's words The midpoint of our 2026 forecasted Adjusted EBITDA net of NCI, represents an increase of 4.8% over our 2025 Adjusted EBITDA net of NCI, of $2.590 billion. release 2026-02-26
Diluted EPS (company-defined) Fiscal 2026	Given $21.74 release 2026-02-26	–	No standard number
The company's words The midpoint of our 2026 forecasted Adjusted EPS-diluted represents an increase of 8.5% over our 2025 Adjusted EPS-diluted of $21.74. release 2026-02-26
Revenue Fiscal 2026	Given $17.36B release 2026-02-26	–	Not reported yet
The company's words The midpoint of our 2026 forecasted net revenues represents an increase of 7.1% over our 2025 net revenues of $17.365 billion. release 2026-02-26
EBITDA (company-defined) Fiscal 2025 (ended 2025-12-31)	Given $2.36B to $2.48B release 2025-02-27 Raised $2.46B to $2.54B release 2025-07-29	–	No standard number
The company's words Our 2025 operating results forecast contains a number of assumptions including, but not limited to, the following: … Our Adjusted EBITDA net of NCI is estimated to be approximately $2.357 billion to $2.484 billion representing an increase of 4.9% to 10.6% over our 2024 Adjusted EBITDA net of NCI of $2.246 billion. release 2025-02-27 Our revised 2025 forecasted Adjusted EBITDA, net of NCI, is estimated to be approximately $2.458 billion to $2.543 billion, representing increases of 4.3% to 2.4% over our original range of 2025 forecasted Adjusted EBITDA, net of NCI. release 2025-07-29
Diluted EPS (company-defined) Fiscal 2025 (ended 2025-12-31)	Given $20.00 release 2025-07-29	–	No standard number
The company's words Our revised 2025 forecasted Adjusted EPS-diluted is estimated to be $20.00 per share to $21.00 per share, representing increases of 8.4% to 5.3% over our original range of 2025 forecasted Adjusted EPS-diluted. release 2025-07-29
Revenue Fiscal 2025 (ended 2025-12-31)	Given $17.02B to $17.36B release 2025-02-27 Narrowed $17.10B to $17.31B release 2025-07-29	$17.36B 10-K filed 2026-02-25	Above the range
The company's words Our 2025 operating results forecast contains a number of assumptions including, but not limited to, the following: … Our net revenues are estimated to be approximately $17.020 billion to $17.364 billion representing an increase of 7.5% to 9.7% over our 2024 net revenues of $15.828 billion. release 2025-02-27 Our revised 2025 forecasted net revenues are estimated to be approximately $17.096 billion to $17.312 billion, representing a change of 0.4% to -0.3% as compared to our original range of 2025 forecasted net revenues. release 2025-07-29
EBITDA (company-defined) Fiscal 2024 (ended 2024-12-31)	Given $1.93B to $2.02B release 2024-02-27 Raised $2.15B to $2.23B release 2024-07-25	–	No standard number
The company's words Our 2024 operating results forecast contains a number of assumptions including, but not limited to, the following: … Our Adjusted EBITDA net of NCI is estimated to be approximately $1.931 billion to $2.019 billion representing an increase of 10.9% to 15.9% over our 2023 Adjusted EBITDA net of NCI of $1.742 billion. release 2024-02-27 Our revised 2024 forecasted Adjusted EBITDA, net of NCI, is estimated to be approximately $2.154 billion to $2.226 billion, representing increases of 11.5% to 10.3% over our original 2024 forecasted Adjusted EBITDA, net of NCI. release 2024-07-25
Diluted EPS (company-defined) Fiscal 2024 (ended 2024-12-31)	Given $15.40 release 2024-07-25	–	No standard number
The company's words Our revised 2024 forecasted Adjusted EPS-diluted is estimated to be $15.40 per share to $16.20 per share, representing increases of 18.5% to 15.7% over our original 2024 forecasted Adjusted EPS-diluted. release 2024-07-25
Revenue Fiscal 2024 (ended 2024-12-31)	Given $15.41B to $15.71B release 2024-02-27 Raised $15.56B to $15.75B release 2024-07-25	$15.83B 10-K filed 2025-02-26	Above the range
The company's words Our 2024 operating results forecast contains a number of assumptions including, but not limited to, the following: … Our net revenues are estimated to be approximately $15.411 billion to $15.706 billion representing an increase of 7.9% to 10.0% over our 2023 net revenues of $14.282 billion. release 2024-02-27 Our revised 2024 forecasted net revenues are estimated to be approximately $15.565 billion to $15.753 billion, representing increases of 1.0% to 0.3% over our original 2024 forecasted net revenues. release 2024-07-25

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-27), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Work on UHS in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/UHS/export.csv") into a cell.